Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy

2003400 citationsJournal Article

Authors

Tomás Berl · Women's College Hospital

Lawrence G. Hunsicker · Women's College Hospital

Julia B. Lewis · Women's College Hospital

Marc A. Pfeffer · Women's College Hospital

Jerome G. Porush · Women's College Hospital

Jean L. Rouleau · Women's College Hospital

Paul Drury ·

Abstract

The composite cardiovascular event rate did not differ in patients with type 2 diabetes and overt nephropathy treated with irbesartan, amlodipine, or placebo in addition to conventional antihypertensive therapy.

Topics & Keywords

Blood Pressure and Hypertension Studies Diabetes Treatment and Management Hormonal Regulation and Hypertension

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Annals of Internal Medicine

Volume 138, Issue 7, pp. 542-549

DOI: 10.7326/0003-4819-138-7-200304010-00010

Field-Weighted Citation Impact: 21.25